[Combined tumor chemotherapy/gene therapy based on the activation of antineoplastic agents by genetic constructions of cytochromes p450].
This article generally reviews new original two-stage approach to an effective treatment of solid cancers by killing tumour cells by the activation of a prodrug after the gene encoding for an activating enzyme has been targeted to the malignant cell. The experimental data concerning gene therapy for malignant tumours by using oxazaphosphorines and cytochrome P450 in a novel combined chemotherapy/cancer gene therapy strategy discussed.
Sokolova
N N
NN
Institute of Biomedical Chemistry RAMS, Moscow. sokolov@ibmh.msk.su
Iatsenko
A N
AN
Pokrovskaia
M V
MV
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D003577:Cytochrome P-450 Enzyme System / Q000235:genetics*; D015971:Gene Expression Regulation, Enzymologic; D015972:Gene Expression Regulation, Neoplastic; D015316:Genetic Therapy; D006801:Humans; D009369:Neoplasms / Q000235:genetics* / Q000628:therapy*; D009374:Neoplasms, Experimental / Q000235:genetics / Q000628:therapy; D011355:Prodrugs / Q000627:therapeutic use
D000970:Antineoplastic Agents; D011355:Prodrugs; D003577:Cytochrome P-450 Enzyme System